Pharmacyte Biotech Inc (OTCMKTS:PMCB) goes for a jump after Goldman Small Cap Research released a research update on the healthcare company. The research firm’s analyst Rob Goldman mentioned in his report that a recent research paper has set the stage for Pharmacyte to move over to first human clinical trials for diabetes.

Update from Goldman research firm

The research updated centered around the biggest development that took place earlier this week, when a member of the company’s International Diabetes Consortium established that the company’s live-cell encapsulation technology can reverse Type 1 diabetes (T1D). The research paper published in the journal named ‘Molecular Therapy’ showed evidence that T1D was reversed in a diabetic mice through transplantation of insulin-producing Melligen cells. However, the effectiveness of these Melligen cells can only be achieved through encapsulating them using Pharmacyte Biotech Inc (OTCMKTS:PMCB)’s Cell-In-A-Box technology.

Further, the trials have moved to the next stage to confirm that the company’s technology keeps the sanctity of the Melligen cells intact. Once proven, Pharmacyte Biotech Inc (OTCMKTS:PMCB)’s technology can replace the traditional forms of insulin and pump therapies, according to Goldman. Given the opportunities present in the $176 billion Diabetes market in the U.S. Pharmacyte Biotech Inc (OTCMKTS:PMCB) has potential to enter the space following the completion of the next stage study.

Appointment of Ex-Alchemia chief

Another interesting development reported by Pharmacyte Biotech Inc (OTCMKTS:PMCB) is the appointment of Thomas Liquard, who is a former Alchemia Ltd and Pfizer Inc (PFE) executive, as a Board of Director. The appointment of Liquard throws enough hints that the company is seriously mulling to establish its brand in the marketplace.

With all the positive developments happening, Pharmacyte Biotech Inc (OTCMKTS:PMCB) soared by 12.34% on Wednesday to close at $0.173. The average number of shares traded stood at 2.90 million on the day.

Previous articlePropanc Health Group Corp (OTCMKTS:PPCH) Set A Record In April
Next articleInnovative Product Opportunities Inc (OTCMKTS:IPRU) Is Running Out Of Innovative Ideas
Steve Kanaval: Portfolio Manager/Writer/ Market Analyst Steve began his career in the Trading Pits in Chicago making markets at the Chicago Mercantile Exchange (NYSE:CME) the Chicago Board of Trade and the CBOE in the early 80’s. He ran the Morgan Stanley Derivative Prop Trading for the firm specializing in Index Arbitrage. He continued his career as a Trader/Portfolio Manager for multiple Hedge Funds during the Internet Boom of the 90’s managing large portfolios. Steve is known as an expert in MicroCap Technology Stocks and the emerging Digital Currency markets as a Portfolio Manager for his Family Office. Steve has managed portfolio’s in volatile asset classes for 3 decades as a commodity trader, hedge fund manager and digital currency trader and miner. Steve publishes his views on the asset classes in a public forum and has published more than 10,000 articles simplifying these complex and volatile assets for readers. His work is published on multiple sites including Bloomberg,,, CryptoCurrencyNews as a paid contributor. His work includes research, journalism and archived video on important market volatility related to stocks, digital currency and other volatile misunderstood asset classes. He offers a humorous, unique insight and the related back stories and drivers for readers interested in volatility and emerging market assets. Full disclosure Steve is long 25 digital currencies and sits on the board of multiple public companies involved in digital currencies, and owns shares in these companies from time to time.